The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwMyeloma 2023 | Updates in the genomics of SMM & multiple myeloma
In this session chaired by Leif Bergsagel, MD, Mayo Clinic, Phoenix, AZ, Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, and Niels Weinhold, PhD, University Hospital Heidelberg, Heidelberg, Germany, explore updates in our understanding of the genomics of smoldering multiple myeloma (SMM) and multiple myeloma. The experts first comment on the definition of smoldering myeloma, before discussing the transition from FISH to next-generation sequencing (NGS) and novel prognostic features to risk stratify patients. The experts then move on to the prognostic value of del(17p) and TP53 mutations, and finish by commenting on clonal substructure and drivers of relapse. This session was filmed at the 16th International Workshop on Multiple Myeloma (iwMyeloma) held in Madrid, Spain.
